More on the Ukraine Black Lung H1N1 mutation.

========================================================================= ========================================================================= =========================================================================

 

Here is the latest from recombinomics:  

 

Ukraine Dead Increase to 344 - Sequences Released
Recombinomics Commentary 22:45
November 18, 2009

1,502,345 Influenza/ARI

85,904 Hospitalized

344 Dead

The above tally is from the latest update from the Ukraine Ministry of Health.  The 344 dead represents an increase of 16 from yesterday's total, which is similar to recent daily increases (see map).  The steady climb in fatal cases highlights the importance of the release of sequences by Mill Hill a WHO regional center in London.

Included in the sequences from 10 isolates were four HA sequences with the receptor binding domain change, D225G, which was found in the one throat and three lung samples.  The change was not found in isolates from nasopharyngeal washes, suggesting D225G may lead to high concentrations of H1N1 in patient's lungs.  The high concentration of virus leads to a cytokine storm that destroys the lungs in a few days.

The finding of D225G in lung tissues raises concerns rergarding sequencing of isolates from nasopharyngeal swabs.  The monitoring of this important genetic change in the receptor binding domain may require sampling of lung tissues or fluids.

==========================================

 

In other related news, it was discovered that President Obama owns a nice chunk of stock in Baxter, a large vaccine manufacturer. Also, U.S. congress is pressing for legal immunity for vaccine makers.

=========================================

 

 

 

==================================================== ==================================================== From the Baxter International website: "DEERFIELD, Ill., October 15, 2009 – Baxter International Inc. (NYSE:BAX) today reported solid financial results for the third quarter of 2009, and provided its fourth quarter and updated full-year 2009 financial outlook.

 

 

 Net income grew 12 percent to $530 million from $472 million reported in the third quarter of 2008. Marketing authorization from the European Commission for CELVAPAN H1N1 pandemic vaccine using Baxter’s Vero cell technology. CELVAPAN H1N1 is the first cell culture-based and non-adjuvanted pandemic influenza vaccine to receive marketing authorization in the European Union." =============================================

 

 

Is that a sweet deal or what? Invest in high profit pharmaceutical companies and then have congress give them legal imminuty if they screw up a vaccine so the investors don't take a hit. How can I get in on that action?